Navigation Links
muscarinic in Medical News

An Increase in the Diagnosed Prevalent Population Will Drive Growth of Nearly $4.3 Billion in the Chronic Obstructive Pulmonary Disease Market

... their patients who receive them. The report finds that as new long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, long-acting muscarinic antagonists (LAMAs), and LABA/LAMA products emerge from clinical development over the next decade, the use of maintenance therapies will continue to i...

TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives

...ronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com . This press release contains forward-looking statements or predic...

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...one for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or un...

New Venture Funding for Alzheimer's Disease Drug Developer

...s that are more effective. MCD-386 is highly selective for the M1-type muscarinic receptor. In preclinical laboratory tests, MCD-386 appears to replace defi...tion, with improved tolerability compared to previously tested M1-selective muscarinic drugs. MCD-386 also appeared to activate alpha-secretase enzymes, which mi...

TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects

...erostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at http://www.torreypinestherapeutics.com . This press release contains forward-looking s...

TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results

...l as announcing results from an ongoing Phase II clinical trial of our lead muscarinic agonist, NGX267, in xerostomia secondary to Sjogren's Syndrome." Ms. Grah...r product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypi...

Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results

...ty to GnRH or GnRH analogs. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or un...

Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

...xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com . This press release contains forward-looking stateme...

TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments

...xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com . This press release contains forward-looking stateme...

TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack

...xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com . This press release contains forward-looking stateme...
muscarinic in Medical Technology

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary end...

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

...neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia. Minster's near-term focus is on the development and commercialization of i...

NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium

...ress of the European Respiratory Society (ERS) in Berlin, Germany. The new data show that NVA237 (glycopyrronium bromide), a novel inhaled long-acting muscarinic antagonist (LAMA), provides sustained 24-hour bronchodilation in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). NVA2...

Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients

...es through the mucosa reaching the minor glands. By inhibiting cholinesterase, acetylcholine accumulates and the elevated concentrations stimulate the muscarinic receptors in the minor glands, improving saliva production. Unlike systemically administered drugs, the local route of administration limits adverse e...

FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents

...ethyl)-8-Methyl-2,8-Diazaspiro[4,5]Decane-1,3,-Dione ([18f]Fluoro-RS-86), A muscarinic Acetylcholine Receptor Agonist" describes the synthesis, tissue distribution and pharmacokinetic profile of 18F labeled RS-86, a known M1 muscarinic receptor agonist. FluoroPharma has developed a novel biomarker approach for...

Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008

...ction was attained in the ANAVEX 1-41 compound at very low doses (0,1mg/kg) in mice. At the same doses there was synergy between Sigma-1 receptors and muscarinic receptors, amplifying the anti-amnesic potential effects, as well as the anti-apoptotic and the anti-oxidative stress potential. Neuroprotection is ...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

...xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com This press release contains forward-looking statemen...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

...xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com . This press release contains forward-looking stateme...

TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel

...xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com . This press release contains forward-looking stateme...

TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds

...lead compounds: AMPA/kainate receptor antagonists tezampanel and NGX426 and muscarinic agonist NGX267. The plan also calls for the expansion of business developme...ultiple dose trial of NGX426 in the second half of the year. muscarinic agonist -- Initiate a Phase II trial of NGX267 in xerostomia, or dry m...
muscarinic in Medical Dictionary

Intoxication

...) on the pituitary-gonadal axis ... Alcoholic Intoxication /blood* Cross-Sectional Studies. Female. Gonadal ... Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare. ... Especially in old patients, intoxications (with cholinergics) should be ... ...
muscarinic in Biological News

Increased sensitivity to nerve signals keeps diabetes at bay

... a new approach to diabetes treatment, the researchers said. Mice in which the pancreas cells that produce insulin, or beta cells, lack so-called M3 muscarinic acetylcholine receptors develop some symptoms of diabetes, including impaired glucose tolerance and reduced insulin release, the authors report. M3 re...
muscarinic in Biological Technology

TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia

LA JOLLA, Calif., March 18 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren's syndrome. The company is conducting a randomized, d...

Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor

FLEXSTATION IS A VERSATILE TOOL FOR ASSAY DEVELOPMENT AND BASIC RESEARCH SIMPLE, RAPID EXPERIMENTAL SET-UP AND DATA ANALYSIS DETERMINE EC 50 AND IC 50 VALUES EXCELLENT FOR ASSAY DEVELOP-MENT AS DEMONSTRATED BY Z FACTOR ...

TorreyPines Therapeutics Reports First Quarter 2009 Financial Results

...hronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com . This press release contains forward-looking statements or predictions. ...

TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements

...chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com . This press release contains forward-looking statements or predictions...

Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed

...hronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com . This press release contains forward-looking statements or predic...

TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results

...hronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com . This press release contains forward-looking statements or predic...

First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated

...rostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.torreypinestherapeutics.com . This press release contains forward-looking statemen...

TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel

...erostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.torreypinestherapeutics.com . This press release contains forward-looking statemen...

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

... for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA(R) XR belong to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or un...

TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds

...NGX267 in xerostomia, or dry mouth, secondary to Sjogren's syndrome. The company has demonstrated the safety of single and multiple doses of NGX267, a muscarinic agonist, in three Phase I trials involving healthy volunteers. -- Complete the shut down of its discovery operations in connection with the planned ...
muscarinic in Biological Dictionary

Transduction

...uction will involve a receptor for the first messenger and may ... Thus, muscarinic cholinergic transduction at all five muscarinic receptor ... 'Signal Transduction ' or 'Signaling' is the process by ...
Other Tags
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
(Date:4/18/2014)... NC Seeds that sprout as soon as they,re planted ... need to be more careful. In the wild, a plant ... day would risk disaster. More than just an insurance policy ... that seed dormancy has long-term advantages too: Plants whose ... rise to more species, finds in a team of researchers ...
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
Other Contents